119 related articles for article (PubMed ID: 11326638)
1. A prognostic value of syndecan-1 in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
4. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
5. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
6. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
[TBL] [Abstract][Full Text] [Related]
7. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
8. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
9. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 expression in gallbladder cancer and its prognostic significance.
Roh YH; Kim YH; Choi HJ; Lee KE; Roh MS
Eur Surg Res; 2008; 41(2):245-50. PubMed ID: 18544939
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
13. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Lundin M; Kokkola A; von Boguslawski K; Haglund C
Int J Cancer; 2001 Jan; 95(1):1-6. PubMed ID: 11241302
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
18. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
[TBL] [Abstract][Full Text] [Related]
19. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
20. [mRNA expression of syndecan-1 and heparanase in relation to tumor progression and prognosis of gastric carcinoma].
Ru GQ; Zhao ZS; Tang QL; Xu WJ
Zhonghua Wai Ke Za Zhi; 2006 Aug; 44(15):1062-4. PubMed ID: 17074248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
